{"schema_version":"secwatch.filing_event.v1","accession":"0001062993-25-012231","form_type":"8-K","ticker":"MDCX","cik":"0001997296","company_name":"Medicus Pharma Ltd.","filed_at":"2025-06-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.658607+00:00","generated_at":"2026-05-18T14:58:21.110751+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Medicus Pharma to acquire Antev Ltd. for ~17% equity stake + up to $65M contingent milestone payments","bullets":["Medicus will issue 2,666,600 common shares (~17% of outstanding) to acquire all Antev shares on a fully diluted basis.","Antev shareholders eligible for up to $65M in contingent consideration tied to FDA Phase 2 and NDA approvals for Teverelix.","Transaction expected to close before end of August 2025, subject to Antev shareholder approval and other conditions.","Antev's lead asset Teverelix targets two indications: acute urinary retention (Phase 2b) and high-CV-risk advanced prostate cancer (Phase 2b).","Consideration shares subject to 9-month staggered lock-up and 36-month voting agreement with Medicus management."],"urls":{"canonical":"https://secwatch.observer/filing/0001062993-25-012231","json":"https://secwatch.observer/filing/0001062993-25-012231.json","markdown":"https://secwatch.observer/filing/0001062993-25-012231.md","text":"https://secwatch.observer/filing/0001062993-25-012231.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1997296/000106299325012231/0001062993-25-012231-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1997296/000106299325012231/form8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T14:58:21.110751+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}